Overview
Study to Investigate the Safety and Pharmacokinetics of SER120 Nasal Spray in Elderly Patients With Nocturia
Status:
Completed
Completed
Trial end date:
2010-11-01
2010-11-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
The purpose of this study is to determine if SER120 nasal spray is well tolerated in 75 years or older nocturic patients.Phase:
Phase 3Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Serenity Pharmaceuticals, Inc.
Criteria
Inclusion Criteria:- Male & female greater or equal to 75 years of age, history of nocturia
Exclusion Criteria:
- CHF, Diabetes, Diabetes Insipidus, Renal Insufficiency, Heptatic Insufficiency,
Incontinence, Illness requiring steroid, current or past urologic maliganancy,
nephrotic syndrome
- Unexplained pelvic masses
- Urinary bladder surgery or radiotherapy
- Sleep apnea